Pharmaceutical The US Food and Drug Administration (FDA) has granted accelerated approval for Novartis’ Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. 8 August 2024